

DAFTAR PUSTAKA

- Baldi I, Engelhardt J, Bonnet C, Bauchet L, Berteaud E, Grüber A, Loiseau H. Epidemiology of meningiomas. *Neurochirurgie*. 2018 Mar;64(1):5-14. doi: 10.1016/j.neuchi.2014.05.006. Epub 2014 Sep 22. PMID: 25249493.
- Begnami, M. D., Palau, M., Rushing, E. J., Santi, M., & Quezado, M. (2007). Evaluation of NF2 gene deletion in sporadic schwannomas, meningiomas, and ependymomas by chromogenic in situ hybridization. *Human pathology*, 38(9), 1345–1350. <https://doi.org/10.1016/j.humpath.2007.01.027>
- Berghoff, A.S., Hielscher, T., Ricken, G., Furtner, J., Schrimpf, D., Widhalm, G., Rajky, U., Marosi, C., Hainfellner, J.A., von Deimling, A. and Sahm, F., 2022. Prognostic impact of genetic alterations and methylation classes in meningioma. *Brain Pathology*, 32(2), p.e12970.
- Biegel, J.A., Rorke, L.B., Packer, R.J. and Emanuel, B.S., 1990. Monosomy 22 in rhabdoid or atypical tumors of the brain. *Journal of neurosurgery*, 73(5), pp.710-714.
- Butts, C. L., Shukair, S. A., Duncan, K. M., Bowers, E., Horn, C., Belyavskaya, E., Tonelli, L., & Sternberg, E. M. (2007). Progesterone inhibits mature rat dendritic cells in a receptor-mediated fashion. *International immunology*, 19(3), 287–296. <https://doi.org/10.1093/intimm/dx1145>
- Cooper, J. and Giancotti, F.G., 2014. Molecular insights into NF2/Merlin tumor suppressor function. *FEBS letters*, 588(16), pp.2743-2752.



Delgado-López, P.D., Cubo-Delgado, E., González-Bernal, J.J. and Martín-Alonso, J., 2020. A practical overview on the molecular biology of meningioma. *Current Neurology and Neuroscience Reports*, 20, pp.1-12.

Champeaux-Depond C, Weller J, Resche-Rigon M. Neurofibromatosis type 2: A nationwide population-based study focused on survival after meningioma surgery. *Clin Neurol Neurosurg*. 2020 Nov; 198:106236. doi: 10.1016/j.clineuro.2020.106236. Epub 2020 Sep 23. PMID: 33002675.

Driver, J., Hoffman, S.E., Tavakol, S., Woodward, E., Maury, E.A., Bhave, V., Greenwald, N.F., Nassiri, F., Aldape, K., Zadeh, G. and Choudhury, A., 2022. A molecularly integrated grade for meningioma. *Neuro-oncology*, 24(5), pp.796-808.

Farah, Y.A., Elmula, I.F., Abushama, H.M., Kreskowski, K. and Liehr, T., 2013. Molecular cytogenetic study of the NF2 gene deletion in meningioma in Sudanese patients. *Balkan Journal of Medical Genetics*, 16(2), pp.29-32.

Garcia-Ruiz, G., Flores-Espinosa, P., Preciado-Martínez, E., Bermejo-Martínez, L., Espejel-Núñez, A., Estrada-Gutierrez, G., Maida-Claros, R., Flores-Pliego, A., & Zaga-Clavellina, V. (2015). In vitro progesterone modulation on bacterial endotoxin-induced production of IL-1 β , TNF α , IL-6, IL-8, IL-10, MIP-1 α , and MMP-9 in pre-labor human term placenta. *Reproductive biology and endocrinology : RB&E*, 13, 115. <https://doi.org/10.1186/s12958-015-0111-3>

Goldbrunner, R., Stavrinou, P., Jenkinson, M.D., Sahm, F., Mawrin, C., Weber, D.C., Preusser, M., Minniti, G., Lund-Johansen, M., Lefranc, F. and Houdart, E., 2021. EANO guideline on the diagnosis and management of meningiomas. *Neuro-oncology*, 23(11), pp.1821-1834.



Hitotsumatsu, T., Iwaki, T., Kitamoto, T., Mizoguchi, M., Suzuki, S.O., Hamada, Y., Fukui, M. and Tateishi, J., 1997. Expression of neurofibromatosis 2 protein in human brain tumors: an immunohistochemical study. *Acta neuropathologica*, 93, pp.225-232.

Huntoon, K., Toland, A.M.S. and Dahiya, S., 2020. Meningioma: a review of clinicopathological and molecular aspects. *Frontiers in Oncology*, 10, p.579599.

Ikeda, S., Kimura, H., Honma, E., Shibata, T., Yamazaki, S., Hashimoto, K., & Eishi, Y. (2000). *No to shinkei = Brain and nerve*, 52(11), 973–977.

Janah, R., Rujito, L., & Wahyono, D. J. (2022). Expressions of Progesterone Receptor of Orbital Meningiomas in Indonesia. *Asian Pacific journal of cancer prevention : APJCP*, 23(12), 4137–4143. <https://doi.org/10.31557/APJCP.2022.23.12.4137>

Lee, S., Karas, P.J., Hadley, C.C., Bayley V, J.C., Khan, A.B., Jalali, A., Sweeney, A.D., Klisch, T.J. and Patel, A.J., 2019. The role of merlin/NF2 loss in meningioma biology. *Cancers*, 11(11), p.1633.

Li, W., Cooper, J., Zhou, L., Yang, C., Erdjument-Bromage, H., Zagzag, D., Snuderl, M., Ladanyi, M., Hanemann, C.O., Zhou, P. and Karajannis, M.A., 2014. Merlin/NF2 loss-driven tumorigenesis linked to CRL4DCAF1-mediated inhibition of the Hippo pathway kinases Lats1 and 2 in the nucleus. *Cancer cell*, 26(1), pp.48-60.

Li, W., Cooper, J., Karajannis, M.A. and Giancotti, F.G., 2012. Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. *EMBO reports*, 13(3), pp.204-215.



Maggio, I., Franceschi, E., Di Nunno, V., Gatto, L., Tosoni, A., Angelini, D., Bartolini, S., Lodi, R. and Brandes, A.A., 2021. Discovering the molecular landscape of meningioma: The struggle to find new therapeutic targets. *Diagnostics*, *11*(10), p.1852.

Maiuri, F., Mariniello, G., Somma, T., Guadagno, E., Corvino, S., Pagano, S., Orlando, V., & Del Basso De Caro, M. (2020). Meningiomas in Premenopausal Women: Role of the Hormone Related Conditions. *Frontiers in oncology*, *10*, 556701. <https://doi.org/10.3389/fonc.2020.556701>

Malueka RG, Hartanto RA, Setyawan NH, Fauzi DNF, Damarjati KR, Rismawan A, Septianastiti MA, Wicaksono AS, Dananjoyo K, Basuki E, Asmedi A, Dwianingsih EK. Association of Hormonal Contraception with Meningioma Location in Indonesian Patients. *Asian Pac J Cancer Prev*. 2022 Mar 1;23(3):1047-1051. doi: 10.31557/APJCP.2022.23.3.1047. PMID: 35345379; PMCID: PMC9360935.

Marosi, C., Hassler, M., Roessler, K., Reni, M., Sant, M., Mazza, E. and Vecht, C., 2008. Meningioma. *Critical reviews in oncology/hematology*, *67*(2), pp.153-171.

Mawrin, C., Chung, C. and Preusser, M., 2015. Biology and clinical management challenges in meningioma. *American Society of Clinical Oncology Educational Book*, *35*(1), pp.e106-e115.

McClatchey, A.I., 2003. Merlin and ERM proteins: unappreciated roles in cancer development?. *Nature Reviews Cancer*, *3*(11), pp.877-883.

Morin, O., Chen, W.C., Nassiri, F., Susko, M., Magill, S.T., Vasudevan, H.N., Wu, A., Vallières, M., Gennatas, E.D., Valdes, G. and Pekmezci, M., 2019. Integrated models incorporating radiologic and radiomic features predict



meningioma grade, local failure, and overall survival. *Neuro-oncology advances*, 1(1), p.vdz011.

Morrow, K.A. and Shevde, L.A., 2012. Merlin: the wizard requires protein stability to function as a tumor suppressor. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*, 1826(2), pp.400-406.

Mota, M. and Shevde, L.A., 2020. Merlin regulates signaling events at the nexus of development and cancer. *Cell Communication and Signaling*, 18(1), pp.1-8.

Nanda, A., Bir, S.C., Maiti, T.K., Konar, S.K., Missios, S. and Guthikonda, B., 2017. Relevance of Simpson grading system and recurrence-free survival after surgery for World Health Organization Grade I meningioma. *Journal of neurosurgery*, 126(1), pp.201-211.

Newton, H.B., 2018. Chemotherapy for meningiomas. In *Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy* (pp. 513-525). Academic Press.

Ogasawara, C., Philbrick, B.D. and Adamson, D.C., 2021. Meningioma: a review of epidemiology, pathology, diagnosis, treatment, and future directions. *Biomedicines*, 9(3), p.319.

Pavelin, S., Becic, K., Forempoher, G., Tomic, S., Capkun, V., Drmic-Hofman, I., Mrklic, I., Lušic, I. and Pogorelic, Z., 2014. The significance of immunohistochemical expression of merlin, Ki-67, and p53 in meningiomas. *Applied Immunohistochemistry & Molecular Morphology*, 22(1), pp.46-49.



Perry, A., Cai, D.X., Scheithauer, B.W., Swanson, P.E., Lohse, C.M., Newsham, I.F., Weaver, A. and Gutmann, D.H., 2000. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. *Journal of Neuropathology & Experimental Neurology*, 59(10), pp.872-879.

Perry, A., 2018. Meningiomas. In *Practical surgical neuropathology: a diagnostic approach* (pp. 259-298). Elsevier.

Petrilli, A.M. and Fernández-Valle, C., 2016. Role of Merlin/NF2 inactivation in tumor biology. *Oncogene*, 35(5), pp.537-548.

Sahm F, Perry A, Deimling AV, et al. Meningioma. In: WHO Classification of Tumours Editorial Board. Central nervous system tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2021 [cited 2023 Feb 12]. (WHO classification of tumours series, 5th ed.; vol. 6). Available from: <https://tumourclassification.iarc.who.int/chapters/45>.

Smith MJ, Higgs JE, Bowers NL, Halliday D, Paterson J, Gillespie J, Huson SM, Freeman SR, Lloyd S, Rutherford SA, King AT, Wallace AJ, Ramsden RT, Evans DG. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset. *J Med Genet*. 2011 Apr;48(4):261-5. doi: 10.1136/jmg.2010.085241. Epub 2011 Jan 28. PMID: 21278391.

Stemmer-Rachamimov, A.O., Gonzalez-Agosti, C., Xu, L., Burwick, J.A., Beauchamp, R., Pinney, D., Louis, D.N. and Ramesh, V., 1997. Expression of NF2-encoded merlin and related ERM family proteins in the human central nervous system. *Journal of Neuropathology & Experimental Neurology*, 56(6), pp.735-742.



Striedinger, K., VandenBerg, S.R., Baia, G.S., McDermott, M.W., Gutmann, D.H. and Lal, A., 2008. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. *Neoplasia*, 10(11), pp.1204-1212.

Sun, C.X., Robb, V.A. and Gutmann, D.H., 2002. Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. *Journal of cell science*, 115(21), pp.3991-4000.

Supartoto, A., Mahayana, I.T., Heriyanto, D.S., Sasongko, M.B., Respatika, H.D., Sakti, D.H., Nurlaila, P.S., Kusnanto, H., Pawiroranu, S. and Haryana, S.M., 2019. Neurofibromatosis type 2 gene mutation and progesterone receptor messenger RNA expression in the pathogenesis of sporadic orbitocranial meningioma. *International Journal of Ophthalmology*, 12(4), p.571.

Yamashima, T., 2009. Human meninges: anatomy and its role in meningioma pathogenesis. *Meningiomas*, pp.15-24.

Yogesha, S.D., Sharff, A.J., Giovannini, M., Bricogne, G. and Izard, T., 2011. Unfurling of the band 4.1, ezrin, radixin, moesin (FERM) domain of the merlin tumor suppressor. *Protein Science*, 20(12), pp.2113-2120.

Zhou, L. and Hanemann, C.O., 2012. Merlin, a multi-suppressor from cell membrane to the nucleus. *FEBS letters*, 586(10), pp.1403-1408.